These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 29167018)
21. Forns index predicts recurrence and death in patients with hepatitis B-related hepatocellular carcinoma after curative resection. Choi WM; Lee JH; Ahn H; Cho H; Cho YY; Lee M; Yoo JJ; Cho Y; Lee DH; Lee YB; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS; Kim CY; Lee HS Liver Int; 2015 Aug; 35(8):1992-2000. PubMed ID: 25556714 [TBL] [Abstract][Full Text] [Related]
22. Neutrophil to lymphocyte ratio changes predict small hepatocellular carcinoma survival. Peng W; Li C; Wen TF; Yan LN; Li B; Wang WT; Yang JY; Xu MQ J Surg Res; 2014 Dec; 192(2):402-8. PubMed ID: 24998425 [TBL] [Abstract][Full Text] [Related]
23. Association between statin use and the prognosis of hepatocellular carcinoma after resection: a nationwide cohort study. Jeon D; Cha HR; Chung SW; Choi J; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Lee SW; Choi WM EClinicalMedicine; 2023 Nov; 65():102300. PubMed ID: 37965429 [TBL] [Abstract][Full Text] [Related]
24. Association of statin treatment with hepatocellular carcinoma risk in end-stage kidney disease patients with chronic viral hepatitis. Kim HW; Joo YS; Kang SC; Koh HB; Han SH; Yoo TH; Kang SW; Park JT Sci Rep; 2022 Jun; 12(1):10807. PubMed ID: 35752695 [TBL] [Abstract][Full Text] [Related]
25. HBV DNA and HBsAg levels as risk predictors of early and late recurrence after curative resection of HBV-related hepatocellular carcinoma. Sohn W; Paik YH; Kim JM; Kwon CH; Joh JW; Cho JY; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC Ann Surg Oncol; 2014 Jul; 21(7):2429-35. PubMed ID: 24619495 [TBL] [Abstract][Full Text] [Related]
26. Statin Use and Survival with Early-Stage Hepatocellular Carcinoma. Jeon CY; Goodman MT; Cook-Wiens G; Sundaram V Cancer Epidemiol Biomarkers Prev; 2016 Apr; 25(4):686-92. PubMed ID: 26908429 [TBL] [Abstract][Full Text] [Related]
27. Better prognosis of hepatic resection combined with antiviral therapy for HBV-related hepatocellular carcinoma with BCLC Stage B/C. Wei Q; Tian H; Luo HX; Zhang YC; Deng YN; Yao J; Li H; Chen GH; Yang Y Asian J Surg; 2017 Nov; 40(6):453-462. PubMed ID: 27321176 [TBL] [Abstract][Full Text] [Related]
28. The association between proton-pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy. Ho CT; Fu CC; Tan EC; Kao WY; Lee PC; Huang YH; Huo TI; Hou MC; Wu JC; Su CW J Gastroenterol Hepatol; 2024 Oct; 39(10):2077-2087. PubMed ID: 38864669 [TBL] [Abstract][Full Text] [Related]
29. Anticancer Effect of Statins in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Lee HL; Lee SW; Jang JW; Bae SH; Choi JY; Yoon SK; Choi HJ; Na GH; You YK; Park IY; Kim DG Liver Transpl; 2022 Mar; 28(3):397-406. PubMed ID: 34374192 [TBL] [Abstract][Full Text] [Related]
30. Antiviral therapy and long-term outcome for hepatitis B virus-related hepatocellular carcinoma after curative liver resection in a Japanese cohort. Sakamoto K; Beppu T; Hayashi H; Nakagawa S; Okabe H; Nitta H; Imai K; Hashimoto D; Chikamoto A; Isiko T; Kikuchi K; Baba H Anticancer Res; 2015 Mar; 35(3):1647-55. PubMed ID: 25750323 [TBL] [Abstract][Full Text] [Related]
31. Surgical Outcomes of Hepatic Resection for Hepatitis B Virus Surface Antigen-Negative and Hepatitis C Virus Antibody-Negative Hepatocellular Carcinoma. Yamashita Y; Imai D; Bekki Y; Kimura K; Matsumoto Y; Nakagawara H; Ikegami T; Yoshizumi T; Shirabe K; Aishima S; Maehara Y Ann Surg Oncol; 2015 Jul; 22(7):2279-85. PubMed ID: 25472646 [TBL] [Abstract][Full Text] [Related]
32. Outcomes after curative hepatectomy in patients with non-B non-C hepatocellular carcinoma and hepatitis B virus hepatocellular carcinoma from non-cirrhotic liver. Kim JM; Kwon CH; Joh JW; Park JB; Lee JH; Kim SJ; Paik SW; Park CK; Yoo BC J Surg Oncol; 2014 Dec; 110(8):976-81. PubMed ID: 25171344 [TBL] [Abstract][Full Text] [Related]
33. Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma: clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection. Li T; Qin LX; Gong X; Zhou J; Sun HC; Qiu SJ; Ye QH; Wang L; Fan J Cancer; 2013 Jan; 119(1):126-35. PubMed ID: 22736338 [TBL] [Abstract][Full Text] [Related]
34. Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B. Huang C; Zhu XD; Ji Y; Ding GY; Shi GM; Shen YH; Zhou J; Fan J; Sun HC BMC Cancer; 2017 Jan; 17(1):58. PubMed ID: 28095820 [TBL] [Abstract][Full Text] [Related]
35. Effect of statins on the recurrence of hepatocellular carcinoma after liver transplantation: An illusion revealed by exposure density sampling. Kim DG; Yim SH; Min EK; Choi MC; Kim MS; Joo DJ; Lee JG Liver Int; 2023 Sep; 43(9):2017-2025. PubMed ID: 37365992 [TBL] [Abstract][Full Text] [Related]
36. Nomogram for preoperative estimation of long-term survival of patients who underwent curative resection with hepatocellular carcinoma beyond Barcelona clinic liver cancer stage A1. Ruan DY; Lin ZX; Wang TT; Zhao H; Wu DH; Chen J; Dong M; Lin Q; Wu XY; Li Y Oncotarget; 2016 Sep; 7(38):61378-61389. PubMed ID: 27542216 [TBL] [Abstract][Full Text] [Related]
37. Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection. Lee JW; Hwang SH; Kim HJ; Kim D; Cho A; Yun M Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1984-1994. PubMed ID: 28695236 [TBL] [Abstract][Full Text] [Related]
38. Relation between antibody to hepatitis B core antigen and survival after curative therapy for non-B non-C hepatocellular carcinoma. Nishikawa H; Osaki Y; Arimoto A; Kita R; Kimura T Anticancer Res; 2013 May; 33(5):2211-9. PubMed ID: 23645778 [TBL] [Abstract][Full Text] [Related]
39. Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center. Franssen B; Alshebeeb K; Tabrizian P; Marti J; Pierobon ES; Lubezky N; Roayaie S; Florman S; Schwartz ME Ann Surg; 2014 Oct; 260(4):650-6; discussion 656-8. PubMed ID: 25203882 [TBL] [Abstract][Full Text] [Related]
40. Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection. He C; Peng W; Li C; Wen TF Medicine (Baltimore); 2017 Apr; 96(16):e6606. PubMed ID: 28422855 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]